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Low grade gliomas (LGGs) are a group of primary brain tumors usually encountered in young patient
populations. These tumors represent a difficult challenge because many patients survive a decade or more
and may be at a higher risk for treatment-related complications. Specifically, radiation therapy is known
to have a relevant effect on survival but in many cases it can be deferred to avoid side effects while
maintaining its beneficial effect. However, a subset of low-grade gliomas manifests more aggressive
clinical behavior and requires earlier intervention. Moreover, the effectiveness of radiotherapy depends
on the tumor characteristics. Recently Pallud et al., [Neuro-oncology, 14(4):1-10, 2012], studied patients
with LGGs treated with radiation therapy as a first line therapy. and found the counterintuitive result
that tumors with a fast response to the therapy had a worse prognosis than those responding late. In this
paper we construct a mathematical model describing the basic facts of glioma progression and response to
radiotherapy. The model provides also an explanation to the observations of Pallud et al. Using the model
we propose radiation fractionation schemes that might be therapeutically useful by helping to evaluate
the tumor malignancy while at the same time reducing the toxicity associated to the treatment.
Keywords: Low Grade Gliomas, Radiotherapy, Mathematical model of tumor response
1. Introduction
Low grade glioma (LGG) is a term used to describe WHO grade II primary brain tumors of astrocytic
and/or oligodendroglial origin. These tumors are highly infiltrative and generally incurable but have
median survival time of > 5 years because of low proliferation (Pignatti et al., 2002; Pouratian & Schiff,
2010). While most patients remain clinically asymptomatic besides seizures, the tumor transformation
c© The author 2008. Published by Oxford University Press on behalf of the Institute of Mathematics and its Applications. All rights reserved.
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to aggressive high grade glioma is eventually seen in most patients.
Management of LGG has historically been controversial because these patients are typically young,
with few, if any, neurological symptoms. Historically, a wait and see approach was often favored in
most cases of LGG due to the lack of symptoms in these mostly young and otherwise healthy adults.
The support for this practice came from several retrospective studies showing no difference in outcome
(survival, quality of life) if therapy was deferred (Olson et al., 2000; Grier & Batchelor, 2006). Other
investigations have suggested a prolonged survival through surgery (Smith et al., 2008). In absence of
a randomized controlled trial, recently published studies may provide the most convincing evidence in
support of an early surgery strategy (Jakola et al., 2012) and waiting for the use of other therapeutical
options such as radiotherapy and chemotherapy. However, the decision on the individual treatment
strategy is based on a number of factors including patient preference, age, performance status, and
location of tumor (Ruiz & Lesser, 2009; Pouratian & Schiff, 2010).
As to radiation therapy the clinical trial by Garcia et al (2004) showed the advantage of using ra-
diotherapy in addition to surgery. However, the timing of radiotherapy after biopsy or debulking is
debated. It is now well known that immediate radiotherapy after surgery increases the time of response
(progression-free survival), but does not seem to improve overal survival while at the same time in-
ducing serious neurological deficits as a result to normal brain damage (Van den Bent, 2005). Overall
survival depends more on patient and tumour-related characteristics such as age, tumour grade, histol-
ogy and neurological function than the details of the plan of radiotherapy treatment. Radioteraphy is
usually offered for patients with a combination of poor risk factors such as age, sub-total resection, and
diffuse astrocytoma pathology (Higuchi et al., 2004).
Mathematical modelling has the potential to select patients that may benefit from early radiotherapy.
Also it may help in developing specific optimal fractionation schemes for selected patient subgroups.
However despite its enormous potential, mathematical modelling has had a limited use with strong focus
on some aspects of radiation therapy (RT) for high-grade gliomas (Rockne et al., 2010; Bondiau et al.,
2011; Konukoglu et al., 2010; Barazzuol et al., 2010). Up to now, no ideas coming from mathematical
modelling have been found useful for clinical application.
There is thus a need for models accounting for the fundamental features of low-grade glioma dynam-
ics and their response to radiation therapy without involving excessive details on the -often unknown-
specific processes but allowing the qualitative understanding of the phenomena involved. The availabil-
ity of systematic and quantitative measurements of LGG growth rates provides key information for the
development and validation of such models (Pallud et al., 2012,b).
In this paper we present a simple mathematical model capturing the key features seen in the response
of LGGs to radiation. Our model incorporates the basic elements of tumor dynamics: infiltration and
invasion of the normal brain by the tumor cells, proliferation and tumor cell death in response to ther-
apy. Radiation therapy is included in an almost parameter-free way that captures the essentials of the
dynamics and explains the relationship between proliferation, response to the therapy and prognosis as
recently reported by Pallud et al. (2012b).
In addition to explaining the counterintuitive observations of Pallud et al. (2012b) the model pre-
sented in this paper can be used to explore different radiation regimes. The analysis to be presented in
this paper suggests the possibility of using radiation therapy with palliative intent and also to test what
the tumor response is and help the oncologists in making the best possible decisions on when and how
to act on the tumor.
Our plan in this paper is as follows. First, in Section 2 we present our model accounting for tumor
cell dynamics and the response of the tumor cells to radiation. Next in Sec. 3 we present the results of
the numerical simulations of the model in different scenarios and study the dependence of the model on
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the different parameters. In Sec. 4 we display some analytical estimates of the typical dynamics of the
tumor response to radiation. In Sec. 5 we discuss some hypothesis suggested from the model that may
be useful for therapy. Finally, in Sec. 6 we summarize our conclusions.
2. Mathematical model for the response of LGGs to radiotherapy
2.1 Tumor cell compartment
In the last years there has been a lot of activity on mathematical models of glioma progression (Murray,
2007; Stamatakos et al., 2006,b; Frieboes et al., 2007; Swanson et al., 2008; Bondiau et al., 2008; Eikenberry et al.,
2009; Tanaka et al., 2009; Konukoglu et al., 2010; Wang et al., 2009; Rockne et al., 2010; Pe´rez-Garcı´a et al.,
2011; Pe´rez-Garcı´a & Martı´nez-Gonza´lez, 2012; Hatzkirou et al., 2012; Badoual et al., 2012; Martı´nez-Gonza´lez et al.,
2012; Gu et al., 2012; Painter and Hillen, 2013). In this paper we will consider a model for the compart-
ment of tumor cells of the simplest possible type: a Fisher-Kolmogorov (FK) type equation (Murray,
2007). More complicated models such as single-cell based models would allow, in principle, to follow
the individual movement of the transformed astrocytes through the brain parenchyma. However, consid-
ering that the basic rules behind a model are more important than the model details, we have discarded
both the use of on-lattice models, which are not realistic when cell motion is considered, and off-lattice
models which assume fixed cell geometries and/or incorporate unknown cell-cell interactions. Besides,
these models often require the estimation of a large number of unknown parameters and the determina-
tion of initial cell configurations, which are extremely difficult to validate in in vivo experiments and/or
using clinical data. Thus, to keep our description as simple as posible we have opted for a continuous
model as follows
∂C
∂ t = D∆C+ρ(1−C)C, (2.1a)
C(x,0) = C0(x), (2.1b)
where C(x, t) is the tumor cell density as a function of time t and the spatial position x and it is
measured in units of the maximal cell density allowed in the tissue C∗ (typically around 103 cell/cm).
∆ = ∑nj=1 ∂ 2/∂x2j is the n−dimensional Laplacian operator.
D is the diffusion coefficient accounting for the average cellular motility measured in mm2/day to
be assumed in this paper to be constant and spatially uniform. Migration in gliomas is not simple and in
fact many authors have proposed that the highly infiltrative nature of human gliomas recapitulates the
migratory behavior of glial progenitors (Suzuki et al., 2002; Dirks, 2001). Here we assume, as in most
models, that glioma cell invasion throughout the brain is basically governed by a standard Fickian diffu-
sion process. More realistic and complicated diffusion terms in gliomas should probably be governed by
fractional (anomalous) diffusion (Fedotov et al., 2011) or other more elaborate terms (Deroulers et al.,
2009) to account for the high infiltration observed in this type of tumors (Onishi et al., 2011) and the
fact that cells do not behave like purely random walkers and may actually remain immobile for long
times before compelled to migrate to a more favorable place. In addition in real brain there are spatial
inhomogeneities expected in the parameter values such as different propagation speeds in white and
gray matter, and anisotropies (e.g. on the diffusion tensor with preferential propagation directions along
white matter tracts). Many papers have incorporated these details (Jbadi et al., 2005; Bondiau et al.,
2008; Konukoglu et al., 2010; Clatz, 2005; Painter and Hillen, 2013) mostly with the intention to make
patient-specific progression predictions. However, the main limitation is the lack of information on the
(many) patient specific unknown details what has limited progresses in that direction. Thus, in order
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to simplify the analysis and focus on the essentials of the phenomena we have chosen to study the
model in one spatial dimension and in isotropic media. It is interesting that up to now only the simplest
models such as those given by Eqs. (2.1) have been used to extract conclusions useful for clinicians
(Swanson et al., 2008; Wang et al., 2009).
The choice of one-dimensional diffusion intends to incorporate qualitatively diffusion phenomena
in the simplest possible way. Front solutions of the 1D FK equation have been extensively studied and
are known to propagate with a minimal speed c = 2
√ρD when starting from still initial data (Murray,
2007). It is interesting that the 1D model recapitulates the most relevant -for us-phenomenology ob-
served in higher-dimensional scenarios. First it is obvious and well-known that front (invasion waves)
solutions of the 1D FK equation also solve higher dimensional version of the equation (Xin, 2000;
Brazhnik and Tyson, 2000). Moreover, those solutions are asymptotically stable (Xin, 2000; Sattinger,
1976) what means that unlike other more complicated non-symmetrical solutions (Brazhnik and Tyson,
2000), they do arise as limits of non symmetric initial data. It is also well known that radially sym-
metric (in 2D) or spherically symmetric (in 3D) travelling wave solutions of FK do not exist in high
dimensions but that symmetric fronts also develop in those scenarios with a non-constant speed that
depends on the local curvature R (Brazhnik and Tyson, 2000; Volpert & Petrovskii, 2009). As the front
grows with time the now radius-dependent front speed is given by c(R) = c−D/R(t). Thus growing
symmetric multidimensional solutions with large curvature radii (R→ ∞) grow with the same speed as
1D fronts (Volpert & Petrovskii, 2009; Gerlee and Nelander, 2012).
In this paper we are interested on the description of low-grade gliomas that typically are very ex-
tended when diagnosed, thus the initial data radius is large and fronts are well developed by then.
Although during the initial stages of tumor development the dimensionality may play a relevant role,
for spatially extended tumors the effect of using higher-dimensional operators is not expected to be
substantial.
Moreover, some of the phenomena to be described later in this paper are found to be essentially
independent of diffusion and a very good qualitative agreement will be found between our simplified
analysis and the growth dynamics of the mean tumor diameter. Taking into account all these evidences
we will keep the system one-dimensional, since our intention is not to provide a detailed quantitative
description of the processes -that in any way would be beyond the reach of a simple model such as FK-
but instead to provide a qualitative description of the dynamics in the simplest possible way. As we
will discuss in detail later, this approach will lead to a simple yet qualitatively correct description of the
response of low grade gliomas to radiotherapy.
The parameter ρ in Eq. (2.1) is the proliferation rate (1/day) its inverse giving an estimate of the
typical cell doubling times. We have chosen a logistic type of proliferation leading to a maximum cell
density C(x, t) = 1. Finally, the tumor evolves from an initial cell density given by the function C0(x)
in an unbounded domain, so we implicitly assume it to be located initially sufficiently far from the grey
matter.
A very interesting feature of model Eqs. (2.1) is the well known fact that a tumor front arises
propagating at the asymptotic (constant) speed of v∗ = 2
√
Dρ what is in very good agreement with the
observed fact that the tumor mean diameter grows at an approximately constant speed (Pallud et al.,
2012).
While many other mathematical models of gliomas incorporate different cell phenotypes, e.g. nor-
moxic (proliferative) and hypoxic (migratory) phenotypes, such as in Martı´nez-Gonza´lez et al. (2012);
Hatzkirou et al. (2012); Pe´rez-Garcı´a & Martı´nez-Gonza´lez (2012), here we focus our attention on LGGs
and as such will consider a single (dominant) tumor cell phenotype. In our model we do not include the
possible existence of different tumor cell populations with different sensitivities to therapy such as stem
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cells since the function and mechanisms of stem cells in glioblastoma are yet under debate (Barrett et al.,
2012; Chen et al., 2012).
2.2 Response to radiation
Radiation therapy has been incorporated in different forms to mathematical models of high-grade glioma
progression (Rockne et al., 2010; Bondiau et al., 2011; Konukoglu et al., 2010; Barazzuol et al., 2010).
In this paper we want to focus our attention on LGGs whose response to radiation is very different to
the one observed in HGGs. Radiation therapy in LGGs typically induces a response that prolongs for
several years after therapy.
Very interesting quantitative data on the response of LGGs to radiation have been reported in a
retrospective study by Pallud et al. (2012). The authors studied patients diagnosed with grade II LGGs
treated with first-line radiotherapy before evidences of malignant transformation. Patients with a post-
RT velocity of diametric expansion (VDE) (Pallud et al., 2012) slower than -10 mm/year were taken as a
subgroup of slowly growing LGGs. Patients with a post-RT VDE of -10mm/year or faster were included
in the group of fast growing LGGs. The authors concluded that the post-RT VDE was significantly faster
in the group with high proliferation. Also in the patients with an available pre-RT VDE, the low pre-RT
VDE subgroup presented a slower VDE at imaging progression. As to the survival time (ST), the post-
radiotherapy VDE carried a prognostic significance on survival time, as the fast post-radiotherapy tumor
volume decrease (VDE at -10 mm/year or faster) were associated with a significantly shorter survival
than the slow post-radiotherapy tumor volume decrease (VDE slower than -10 mm/year).
The very slow response to radiotherapy, leading to tumor regression lasting for several years is diffi-
cult to understand in the context of the standard linear quadratic model in which damage is instantaneous
and leads to cell death early after radiation therapy. However a key aspect of the cell response to radia-
tion is that irradiated cells usually die because of the so-called mitotic catastrophe after completing one
or several mitoses (Van der Kogel & Joiner, 2009). This means that slowly proliferating tumors, as it is
the case of LGGs with typical low proliferation indexes between 1% and 5% in pathological analyses
need a very long time to manifest the accumulated cell damage that cannot be repaired.
Thus, in order to capture in a minimal way the response of the tumor to radiation we will complement
equation (2.1) for the density of functionally alive tumor cells C(x, t) with an equation for the evolution
of the density of irreversibly damaged cells after irradiation Cd(x, t). Our model for the evolution of
both tumor cell densities will be given by the equations
∂C
∂ t = D∆C+ρ(1−C−Cd)C, (2.2a)
∂Cd
∂ t = D∆Cd −
ρ
k (1−C−Cd)Cd . (2.2b)
The first equation is a Fisher-Kolomogorov type equation describing the evolution of tumor cells C(x, t).
The saturation term includes the total tumor cell density, i.e. both the functional tumor cells and those
damaged by radiation Cd(x, t). The evolution of cells irreversibly damaged by radiation is given by
Eq. (2.2b). As it is well described in the literature (Van der Kogel & Joiner, 2009), most of these cells
behave normally until a certain number of mitosis cycles, thus we will consider that after an average of
k mitosis cycles these cells die resulting in a negative proliferation. The longer survival time kτ with
τ = 1/ρ being the tumor population doubling time, results in a reduced proliferation potential ρ/k, that
is the coefficient used for the negative proliferation term. Thus, the parameter k in Eq. (2.2b) has the
meaning of the average number of mitosis cycles that damaged cells are able to complete before dying.
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As with the normal population the number of cells entering mitosis depends in a nonlinear way on both
tumor cell populations (cf. last term in Eq.(2.2b)).
We will assume a series of radiation doses d1,d2, ...,dn given at times t1, t2, ..., tn. The initial data for
the first subinterval will be given by the equations
C(x, t0) = C0(x), (2.3a)
Cd(x, t0) = 0. (2.3b)
The evolution of the tumor follows then Eqs. (2.2) until the first radiation dose d1, given at time t1.
The irradiation results in a fraction of the cells (surviving fraction) able to repair the radiation-induced
damage given by S f (d1) and a fraction 1−S f (d1) of cells unable to repair the accumulated damage thus
feeding the compartment of irreversibly damaged cells. The subsequent evolution of the populations is
again given by Eqs. (2.2) until the next RT dose is given. In general after each irradiation event we get
C(x, t+j ) = S f (d j)C(x, t
−
j ), (2.3c)
Cd(x, t+j ) = Cd(x, t
−
j )+
[
1− S f (d j)
]
C(x, t−j ), (2.3d)
where S f (d j) is the survival fraction after a dose of radiation d j, i.e. the fraction of damaged tumor cells
after irradiation that are not able to repair lethal damage and are incorporated to the compartment of
damaged cells. For the doses to be considered independent the interval between doses (typically 1 day)
has to be larger than the typical damage repair times (of the order of hours). The evolution of both cell
densities between irradiation events is given by the PDEs (2.2).
2.3 Parameter estimation
Eqs. (2.2) together with the initial conditions for each subproblem (2.3) define completely the dynamics
of a low grade glioma in the framework of our simplified theoretical approach.
We have chosen the parameters to describe the typical growth patterns of LGG. For the proliferation
rate we have chosen typical values to be small and around ρ = 0.003 day−1 (see e.g. Badoual et al.
(2012)), that give doubling times of the order of a year. Specifically we have considered values ranging
from ρ = 0.001 day−1 for very slowly growing LGGs to ρ = 0.01 day−1. For the cell diffusion coef-
ficient we have taken values around D = 0.0075 mm2 /day (Jbadi et al., 2005). This choice, together
with the previously chosen ρ leads to asymptotic tumor diameter growth speeds given by v = 4√Dρ of
the order of several millimeters per year, in agreement with typical diametric growth speeds of LGGs
(Pallud et al., 2012). However the fact that the asymptotic speed is only reached when the tumor cell
density is around one may require taking larger values of D to match the real growth speeds.
As to the radiobiological parameters, being gliomas very resistant to radiation we have taken values
in the range S f (1.8 Gy)≡ SF1.8 ∼ 0.9 considering the median survival fraction value 0.83 after one dose
of 2 Gy given by Barazzuol et al. (2010) .
Finally, the average number of mitosis cycles completed before the mitotic catastrophe occurs is
difficult to estimate. This parameter intends to summarize in a single number a complex process in
which a cell hit by radiation and its progeny die after some more mitosis cycles leading to a final
extinction after a variable time. Death by mitotic catastrophe implies a minimal value of k = 1 and to
allow for some more time we may choose values in the range k = 1−3 (Van der Kogel & Joiner, 2009).
We will show later that the choice of this parameter has a limited effect on the model dynamics and that
in standard fractionation schemes there may be biological reasons to take it as k = 1.
Our typical choices for the full set of model parameters is summarized in Table 1.
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Variable Description Value (Units) References
C∗ Maximum tumor 106 cell/cm2 Swanson et al. (2008)
cell density
D Diffusion coefficient for 0.01 mm2 /day Jbadi et al. (2005)
tumor cells
ρ Proliferation 0.00356 day−1 Badoual et al. (2012)
rate
SF1.8 Survival fraction ∼ 0.9 Barazzuol et al. (2010)
for 1.8 Gy
k Average number of mitosis 1-3 Van der Kogel & Joiner (2009)
cycles completed before the
mitotic catastrophe
Table 1. Typical values of the biological parameters in the model of LGG evolution.
In this paper we will fix the dose per fraction in agreement with the standard fractionation schemes
for LGGs to be 1.8 Gy, the only relevant parameter is the survival fraction SF1.8 that will be taken to be
around SF1.8 ∼ 0.9, as discussed above. In many examples we will choose the radiotherapy scheme as
the standard fractionation of a total of 54 Gy in 30 fractions of 1.8 Gy over a time range of 6 weeks (5
sessions per week from monday to friday).
3. Results
3.1 Computational details
We have studied the evolution of the tumor diameter using our model equations (2.2) and (2.3). To solve
the partial differential equations we have used standard second order finite differences both in time and
space. Since the tumor diameter in the framework of this model tends to grow linearly in any spatial
dimension we have focused on the simplest one-dimensional version of the model. We have checked
with simulations in higher dimensions that the dynamics is essentially the same and thus have sticked
to the simplest possible model. To avoid boundary effects and focus on the bulk dynamics, we have
assumed our computational domain to be much larger than the tumor size.
In each simulation we have computed the tumor diameter as the distance between the points for
which the density reaches a critical detection value Cth that provides a signal in the T2 (or FLAIR)
MRI sequence. Although which is that precise value is a debated question and in fact depends on the
thresholds used in the images, we have assumed that Cth ∼ 0.05− 0.07. This is in agreement with the
reported value of cellular density about 0.16 for detection (Swanson et al., 2008) and a normal tissue
density of about 0.1. In agreement with previous studies we take a fatal tumor burden (FTB) size of 6
cm in diameter (Swanson et al., 2008; Wang et al., 2009). As parameters containing useful information
we have computed: the time in which the tumor starts regrowing after the therapy, usually called in
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FIG. 1. (a) Tumor diameter evolution for two different values of the proliferation: ρ = 0.00356 day−1 , ρ = 0.00712 day−1. Other
parameter values are: D = 0.0075 mm2/day, critical detection value Cth = 0.07, SF1.8 = 0.90 and k = 1. The initial tumor cell
densities are taken as Cd(x,0) = 0,C(x,0) = 0.4sech (x/6) with x measured in mm, what gives an initial tumor diameter of 28.8
mm. Radiotherapy follows the standard scheme (6 weeks with 1.8 Gy doses from monday to friday) and starts at time t = 0.
Circles denote measurements every three months that would correspond to a close follow-up of the patient. The upper dashed line
(horizontal) shows the fatal tumor burden size taken through this paper to be 6 cm as discussed in the text. (b) Evolution of the
tumor cell amplitudes A(t) = maxx |C(x,t)| and B(t) = maxx |Cd(x,t)| during the first 200 days showing the early response to the
therapy for ρ = 0.00356 day−1.
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FIG. 2. Dependence of the (a) survival time (solid line), growth delay (dashed line), time to tumor progression (dotted line) and
(b) maximal reduction in diameter as a function of ρ . The curves summarize the outcome of many individual simulations with
initial data Cd(x,0) = 0,C(x,0) = 0.2exp
(−x4/81920) with x measured in mm that gives an initial tumor diameter of 33.80 mm.
Radiotherapy follows the standard scheme (6 weeks with 1.8 Gy doses from monday to friday) and starts at time t = 0. Other
parameters used in the simulations are as in Fig. 1.
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clinical practice time to tumor progression (TTP), the time for which the tumor size equals its initial
size -denoted as growth delay (GD)- and the time for which the tumor size equals the FTB or survival
time (ST).
We have studied a broad range of parameter values corresponding to the possible range of realistic
values in the framework of our simple description of the tumor dynamics and its response to radiother-
apy. We have also taken different types of initial data ranging from more localized (such as gaussian
initial profiles) to more infiltrative (such as sech type functions). In what follows we summarize our
results.
3.2 Tumor proliferation rate determines the response to radiotherapy
In a first series of simulations we have studied the dependence of the evolution of the tumor diameter on
the proliferation rate. Fig. 1(a) shows the evolution of the tumor diameter for two different proliferation
rates ρ = 0.00356 day−1 and ρ = 0.00712 day−1 (Fig. 1). In the first case of low proliferation, the
tumor responds more slowly to therapy as measured by the speed of tumor regression (decrease in size)
but the total response time is significantly longer, being the time to tumor progression of 16.9 months
against 8.2 months in the later case. Also the growth delays are 14.7 months for the faster proliferating
tumor against 29.9 months for the less proliferative one. Finally the “virtual patient” with the slowly
proliferating tumor survives much longer than that with the more proliferative one. This is just an
example of a tendency shown in all of our simulations where more aggressive tumors respond earlier to
the therapy.
It is remarkable that this fact is in full agreement with the results from Pallud et al. (2012b). Our
model based on reasonable biological assumptions leads to a long remission time (e.g. in Fig. 1 of
about 3 years) much larger than the treatment duration (6 weeks) and negatively correlated with the
tumor proliferation rate. As a second relevant finding, also seen in the results shown by Pallud et al.
(2012b), we observe that tumors responding faster have also shorter regrowth time.
Fig 1(b) shows the dynamics of the maximum density of tumor cells (A(t) = maxx C(x, t)) and
damaged tumor cells (B(t) = maxxCd(x, t)). As could be expected the amplitude of functionally alive
tumor cells decreases during the therapy with the exception of the breaks in the weekends were a small
increase is seen and correspondingly the amplitude of damaged tumor cells grows after every irradiation
and for the full treatment period (6 weeks = 42 days). After t = 42 days the population of tumor cells
starts a slow recovery while the population of damaged cells declines in a much longer time scale.
However, the width of the total tumor population evolves only in the slow time scale and does not
display any effects during the treatment period.
It is important to emphasize that this behavior is not the result of a fortunate choice of the parameters
but a generic behavior as we have confirmed through a large number of simulations covering the full
clinically relevant parameter space. As an example, in Fig. 2 we show how the variation of ρ over a
broad range of values leads to the same conclusion. Larger proliferation values accelerate the response
but lead to earlier regrowth and as such, shorter growth delays and survival times [Fig. 2(a)]. Our simu-
lations also point out that the maximum volume reduction is only weakly dependent on the proliferation
rate ρ [Fig. 2(b)], the smaller the proliferation rates the larger the maximum reduction in diameter. This
fact is also in very good agreement with the results of Pallud et al. (2012b) (see e. g. Fig. 2 bottom of
their paper).
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FIG. 3. (a) Tumor diameter evolution for three different values of k = 1 (triangles), k = 2 (squares), and k = 3 (circles) for
ρ = 0.00712 day−1. Other parameters are as in Fig. 2. The upper dashed line (horizontal) corresponds to the fatal tumor burden
size. Radiotherapy follows the standard scheme (6 weeks with 1.8 Gy doses from monday to friday) and starts at time t = 0. It
is clear that for this set of parameters the survival time does not depend on k despite the differences in the maximum diameter
reduction achieved by the therapy. (b) Maximum diameter reduction for different values of the mean number of mitosis completed
before cell death k between 1 and 3. (c) Survival time and growth delay as a function of k.
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3.3 The role of the number of mitosis before clonogenic cell death
It is well known that most cells die after irradiation through the so-called mitotic catastrophe, i.e. due to
incomplete mitosis, after completing one or several mitosis cycles. However, the specific choice of the
parameter k is not a priori obvious although a number between one and three is to be expected a priori
from previous experience in vitro (Van der Kogel & Joiner, 2009). To get some information on how our
model result’s depend on this parameter we have explored numerically the range k = 1− 3.
Our results are summarized in Fig. 3. First, in Fig. 3(a) we show typical evolutions of the tumor
diameter for three different values of k = 1 (triangles), k = 2 (squares), and k = 3 (circles) for ρ =
0.00712 day−1. It is clear that although the diameter reduction depends on k [Fig. 3(b)], the specific
choice of this parameter does not affect the more relevant parameters such as the growth delay and the
total survival and only weakly the growth delay [see Fig. 3(a),(c)]. From this and other simulations we
think the specific choice of this parameter does not have a crucial role on the clinically relevant features
dynamics.
In addition, although in-vitro irradiation of cells with a single dose allows cells to complete a few
mitosis cycles, the accumulation of many doses in real treatment schedules implies that a typical cell
receives a lot of DNA damage. This will probably make very difficult for cells in vivo to progress
after the first mitosis, thus making reasonable to take k = 1. This fact, together with the previous result
on the independence of the clinically relevant endpoints on k makes the choice of k = 1 a reasonable
assumption not expected to have a relevant impact on the final results.
3.4 The role of cell motility
We have also analyzed the role of the variation of the cell motility (invasion) parameter D. The typical
outcome of several simulations for different values of this parameter is shown in Fig. 4. It is clear from
Fig. 4(a) that cell motility does not affect too much the dynamics of the response to the therapy except
for long times because of the effect of the mobility on the asymptotic velocity of diametric expansion
v = 4
√ρD. This manifests in the independence of the time to tumor progression and growth delay on
D and the relevant impact of this parameter on the survival time (Fig 4(b)).
3.5 Deferring radiotherapy does not affect survival time
One clinical facts on radiotherapy of LGGs that has been proven in the last years is that deferring
radiotherapy has no significant impact on the survival time (Bauman et al., 1999; Van den Bent, 2005).
To test if our model presents this behavior we have run several series of simulations with different delays
in the start of the radiotherapy and compared the outcome. Typical results are shown in Fig. 5. The
results of the model fully agree with this very well known fact what gives us more confidence in the
model’s predictive power, despite its simplicity.
3.6 Splitting doses does not affect survival time
We have studied the response of the tumor to radiotherapy under many different fractionation schemes
maintaining the dose per fraction to be 1.8 Gy. Surprisingly all of the studied fractionations lead to very
similar results for the virtual patient’s survival time. A typical example is shown in Fig. 6.
Although we have not tried every possible combination, this fact points out the difficultity of con-
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FIG. 4. (a) Tumor diameter evolution for three different values of D = 0.001 mm2day−1 (circles), D = 0.007 mm2day−1 (trian-
gles), and D= 0.021 mm2day−1 (squares) for ρ = 0.00356 day−1 . Other parameters and initial data are as in Fig. 2. Radiotherapy
follows the standard scheme (6 weeks with 1.8 Gy doses from monday to friday) and starts at time t = 0. It is clear that for this
set of parameters the early response to the therapy does not depend on D while the asymptotic growth does (b) ST, GD and TTP
as a function of D. Only the ST depends substantially on the cell motility D.
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FIG. 5. Evolution of an initial tumor density given by C(x,0) = 0.2exp(−x2/(2w2)),Cd(x,0) = 0 for w = 6, being (x,w) measured
in mm, and parameter values D = 0.01 mm2/day, ρ = 0.004 day−1 , SF1.8 = 0.9 and k = 1. Radiotherapy follows the standard
scheme (6 weeks with 1.8 Gy doses from monday to friday) and starts at a given time TRT after the begining of the simulation for
t = 0. Shownare (a) Tumor diameter evolution for three different values of TRT = 6 months (solid line, circles), TRT = 18 months
(dashed line, squares), TRT = 30 months (dotted line, triangles). (b) Survival time (solid line), growth delay (dashed line) and time
to tumor progression (dotted line) as a function of the delay TRT in the start of the radiotherapy
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FIG. 6. Tumor diameter evolution for parameter values D = 0.007 mm2/day, ρ = 0.00356 day−1, initial data as in Fig. 1 and
two different fractionations of the total dose. The solid line corresponds to the tumor evolution under 30 doses of 1.8 Gy given
from monday to friday for six consecutive weeks starting 1 week after t = 0. The dashed line corresponds to the tumor diameter
evolution under the same fractionation scheme for the first three weeks and then deferring the remaining 15 doses for one year.
Despite the time of response is shorter, the final survival time is the same in both fractionation schemes.
structing specific fractionation schemes leading to a better outcome than those currently in use. How-
ever, the results of Fig. 6 have interesting potential practical applications as will be discussed in Sec.
5.
4. Some analytical estimates
The model equations given by Eqs. (2.2), though simple, do not have known analytical solutions al-
lowing for the direct calculation of the clinically relevant quantities, i. e. the time to tumor progression
(tTTP), the growth delay (tGD) and the time to fatal tumor burden. Even for the simplest version of
the Fisher-Kolmogorov equations only a limited number of solutions are known for specific parameter
values (Murray, 2007; Ablowitz & Zeppetella, 1979).
Here we present some back-of-the-envelope calculations that may help in getting a qualitative idea
of the typical dynamics of the tumor response to radiation. The basic idea behind our estimates is
that during some time after irradiation the dominant component of the dynamics is the refilling of the
compartment of the proliferating tumor cells and diffusion acts on a longer time scale being responsible
for the asymptotic front speed (see e.g. Fig. 4(a)) but having only a negligible influence both on the
time to tumor progression and the growth delay (Fig. 4(b)).
We will assume the tumor densities shortly after irradiation to be small enough to allow for the
nonlinear terms to be neglected (it is in agreement to the low cellularity characteristic in LGG histologic
samples). This is obviously true for the tumor compartment whose typical cell densities after irradiation
are small until the tumor refills the space. As to the damaged tumor cell compartment its maximal
density is of the order of the maximal initial tumor cell density (about 0.3-0.4) but decays in space to
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smaller cell densities and will be assumed to contribute only through the leading linear terms.
As a final assumption, we will assume the total treatment time to be short in comparison with the typ-
ical proliferation times so that the effect of the radiotherapy will be incorporated through a modification
of the pretreatment tumor cell density C0(x). Thus, for our rough estimates we will take
C(x,0) = SnfC0(x), (4.1a)
Cd(x,0) =
(
1− Snf
)
C0(x). (4.1b)
Our set of hypothesis leads to a very simple evolution law for the total densities, valid for short times
C(x, t) ≈ SnfC0(x)eρt , (4.2a)
Cd(x, t) ≈
(
1− Snf
)
C0(x)e−ρt/k, (4.2b)
so that for some time after the therapy, the total tumor cell density CT (x, t) can be roughly approximated
by
CT (x, t)≈
[
Snf eρt +
(
1− Snf
)
e−ρt/k
]
C0(x), (4.3)
where A(t)≡ Snf eρt +
(
1− Snf
)
e−ρt/k provides an estimate of the tumor maximum density as a function
of time. From this simple formula we can estimate the growth delay time since it would correspond to
the time tGD > 0 such that
Snf eρtGD +
(
1− Snf
)
e−ρtGD/k ≈ 1. (4.4)
Although Eq. (4.4) is an algebraic equation with no simple explicit solutions by the time regrowth
happens we can expect the first term to have a very small contribution while the second one would
dominate what gives
tGD ≈ 1ρ log
(
1
Snf
)
≈ n
(
1− S f
)
ρ (4.5)
This equation incorporates the fact that the growth delay time does not depend much neither on the
diffusion parameter D (see e.g. Fig. 4(b)), nor on the number of mitosis before cell death for damaged
cells (see e.g. Fig. 3(c)) and points out a direct simple dependence of this time on the survival fraction,
number of doses and proliferation parameter. Moreover the dependence of tGD on ρ is ∼ 1/ρ what
resembles closely the dependence depicted in Fig. 2. We can also get estimates for the time to tumor
progression since it corresponds to the point of minimum amplitude, corresponding to the time tTTP such
that A′(tTTP) = 0
d
dt
[
Snf eρt +
(
1− Snf
)
e−ρt/k
]
= 0, (4.6)
what leads to
tTTP =
1
ρ
(
1+ 1k
) log
(
1− Snf
Snf
)
≃ n
(
1− S f
)
ρ
(
1+ 1k
) (4.7)
While these estimates are obtained as rough approximations for the response to radiation, they pro-
vide a very reasonable agreement with the results of direct numerical simulations of Eqs. (2.2). For
instance in Fig. 7(a) we compare the results for the growth delay and time to tumor progression pro-
vided by Eqs. (4.5) and (4.7) with the results from Eqs. (2.2) for a typical set of parameters and varying
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FIG. 7. Comparison of the estimates for tGD (circles) and tTTP (squares) obtained from Eqs. (4.5) and (4.7) and their exact values
(lines) obtained from numerical simulations of Eqs. (2.2) in different scenarios. In all cases D = 0.007 mm2/day, S f = 0.9 and
k = 1 and initial data are as in Fig. 1. (a) Dependence on the proliferation parameter ρ for a fixed number of doses n = 30
following the standard fractionation scheme. (b) Dependence on the number of doses n for fixed ρ = 0.002 day−1 .
18 of 26 V. M. P ´EREZ-GARC´IA et al.
the proliferation parameter ρ . In Fig. 7(b) we compare the predictions for tTTP and tGD given by Eqs.
(4.5) and (4.7) for different values of the number of radiation fractions n, with the simulations of the full
PDEs.
In addition to these quantities it is possible to use Eq. (4.3) to get estimates for the conditions of
response to therapy (A′(0)< 0), i.e.
A′(0) = ρSnf −ρ
(
1− Snf
)
/k < 0. (4.8)
This leads to the result that an estimate for the minimal number of doses leading to response is about
n >− log(1+ k)
logS f
. (4.9)
Interestingly, this number is independent of ρ and for the typical values of S f used in our simulations
we get a minimal number of sessions around 7 and 9. We have compared this estimate with the results
of direct simulations of Eqs. (2.2) and found a very good agreement. For instance, taking typical initial
data and parameter values C(x,0) = 0.4sech(x/11), ρ = 0.00356 day−1, k = 1, D = 0.0075 mm2/day
and S f = 0.92 we get response for n > 10 that is very close to the theoretical estimate computed from
Eq. (4.9) which is n > 9. The same happens for other parameter choices.
Finally, neither the growth delay as given by Eq. (4.5) nor the time to tumor progression (4.7) depend
on the initial amplitude or time t0. This means that radiation can be deferred with no effect on these
quantities, what matches very well the behavior observed in Fig. 5(b).
5. Discussion and therapeutical implications
The intention of this paper is to propose a simple mathematical model adding radiation therapy in a
minimal way to the simplest model of tumor progression. Despite its simplicity, the model reproduces
many of the well-known facts of RT of LGGs as well as the recent results by Pallud et al. (2012b). The
fact that the model reproduces so well what is known makes us wonder if it can be used to obtain any
new information and/or to propose novel ideas with potential of translational application. In this section
we make several proposals based on the mathematical model.
The first one is based on the fact, discussed in Sec. 3.6, that deferring part of the treatment does
not affect survival time. This concept opens the door to dose fractionation approaches were part of
the radiation is given right after surgery as an adjuvant therapy and the remaining radiation is given on
progression (or later), thus controlling early the tumor while deferring in time the appearance of side
effects. A specific way of implementing this idea would be to complete the radiation therapy exactly
when the tumor size is minimal so that the irradiated volume is substantially smaller than initially and the
side effects due to so called volume effect would be reduced. Thus, instead of waiting till the tumor has
extended substantially the first dose would be given right after resection and the second one on minimal
volume. The fact that the tumor volume irradiated would be smaller might allow for the consideration
of dose scalation protocols while maintaining the side effects under control.
A second implication of our model is that delivery of a reduced radiation dose larger than the mini-
mal response dose (e.g. 30 Gy) should have a verifiable effect on tumor size following subtotal surgery
up front as adjuvant therapy. Monitoring the response of the tumor to radiation one could get an idea
of its malignancy due to the relation between response time and proliferation and correlate the finding
with the proliferation index obtained through immunohistochemistry when available. The toxicity of
this approach for the normal brain is low since 30 Gy is about the same level the prescriptions for even
full-brain irradiation under metastatic spreading, a dose that is very well tolerated by the brain.
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Having an early estimate of the tumor aggressiveness is a potentially interesting information since in
addition to making survival estimates (from the tumor parameters ρ ,D) it would allow to discriminate
tumors that are not as benign as initially thought. A first reason is that the tumor may have transformed
to some degree into a more malignant one. This happens sometimes when the histological analysis is
old, and by the time RT starts the tumour has become malignant. A different relevant source of error
on diagnosis is sampling error if the histology was obtained through biopsy. In fact, biopsy is known to
underestimate glioma grade in roughly 30% of cases (Muragaki et al., 2008) due to localized malignant
transformation outside the biopsy location. Those tumors with high proliferation values obtained from
the mathematical modeling should be expected to have early (radiological) malignant transformation
and then MRI’s should be taken in shorter intervals, as suggested e.g. by (Pallud et al., 2012b) for fast
growing tumors. A final therapeutic option for those tumors with fast growth and/or expected early
malignant transformation should be to consider another surgery (if feasible) or to start chemotherapy.
Thus, taking together our two ideas we could make specific recommendations: for tumors with a
high risk of malignant transformation, i.e. short regrowth time our suggestion would be to complete the
full radiation dosing while for those growing slowly one could wait either until the malignant transfor-
mation or to the point were the tumor starts regrowing.
6. Conclusions
In conclusion, in this paper we have constructed a mathematical model combining the standard Fisher-
Kolmogorov dynamics for tumor cells with a model for the response to radiation based on radiobiolog-
ical facts. Our equations provide a theoretical link between proliferation and response to therapy that is
one of the main results of this paper. The model predicts that tumors with high proliferation will respond
faster to RT than those with slower proliferation values. However this regression would only be transient
and a regrowth is expected early in those tumors responding faster. This fact, despite being somewhat
counterintuitive has been confirmed in very recent retrospective studies by Pallud et al. (2012b). The
model also displays the observed behavior that deferring RT does not affect survival time.
The equations allow to obtain analytical estimations for the growth delay time, time to tumor pro-
gression and conditions of response to therapy such as the minimal number of doses leading to response.
In addition to describing the known features of the response of LGGs to radiotherapy the model
allows to get interesting predictions that may be amenable to further research. One of them is to follow
a split-dose approach with a fraction of the total amount of radiation being given after surgery and
the remaining on progression. This methodology would allow to get information on the tumor growth
parameters what may lead to, estimates of the expected time to malignant transformation, survival, etc.,
while at the same time reducing toxicity.
We hope that our results will stimulate further colaborative studies directed to improve the quality
of life of patients suffering this devastating disease.
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A. Study of the system without diffusion
A.1 Motivation and simplified model
The main focus of the paper is the obtention of results on LGG progression that is related to the tumor
size if the transition to malignancy is not taken into account. However it is interesting to note that a
lot of information on the kinetic part of equations (2.2) can be obtained. Thus in this appendix we will
study the pair of ordinary differential equations
dA
dt = ρ(1−A−B)A, (A.1a)
dB
dt = −
ρ
k (1−A−B)B. (A.1b)
were now both A(t),B(t) are positive functions depending only on time and describing the evolution of
both tumor cell populations in systems without spatial inhomogeneities. The effect of radiotherapy given
at times (t1, ..., tn) with doses (d1, ...,dn) and survival fractions (S f (d1), ...,S f (dn)) in this simplified
model is given by the equations
A(t+j ) = S f (d j)A(t
−
j ), (A.2a)
B(t+j ) = B(t
−
j )+
[
1− S f (d j)
]
A(t−j ). (A.2b)
A.2 Analysis of Eqs. (A.1)
Since Eqs. (A.1) correspond to an autonomous planar dynamical system, the possible dynamics in the
phase space can be completely understood. First of all notice that there are two families of equilibria.
First, the equilibrium point with (A,B) = (0,0) and then the line of points R satisfying A+B = 1, with
A,B > 0. The first one is a saddle point, thus unstable and means that tumor cells tend to regrow no
matter how small is their density. As to those in R = {(a,1− a), 0 < a < 1} the Jacobian matrix reads
J(R) = ρ
( −a −a
(1− a)/k (1− a)/k
)
(A.3)
The eigenvalues of this Jacobian matrix are given by
λ1 = 0, λ2 =
ρ
k (1− a)−ρa,
and the corresponding eigenvectors are (1,−1) and (1,−(1− a)/ka), respectively (for λ2 6= 0). The
equilibrium points on R are nonhyperbolic points. If a < 1/(k + 1) then the fixed point (a,1− a)
possesses a local unstable manifold and a local center manifold. Otherwise, (a,1− a) has a local stable
manifold and a local center manifold. Thus, to get a heteroclinic orbit joining two points, say (a1,1−a1)
and (a2,1− a2), with a2 > a1, it is a necessary condition that a2 > 1/(k+ 1) and a1 < 1/(k+ 1).
A straightforward application of the center manifold theory shows that the center manifold of R is
the same set, i.e., W c(R) = R. Moreover, the points of R satisfying a < 1/(k+ 1) are unstable, while
the points over the center manifold satisfying a > 1/(k+ 1) are stable.
The explicit form of the equation of the orbits can be obtained from Eqs. (A.1)
dA
dB =−k
A
B
(A.4)
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FIG. 8. Phase portrait of the dynamical system (A.1). Shownare the velocity field (arrows) and some orbits (blue) including some
heteroclinic orbits connecting unstable equilibrium points on R with stable equilibria on the same set (blue). Also in red are
shown the stable and unstable manifold of the point (0,0) (located on the axes), and the manifold of equilibria R. The red lines
determine the limits of the invariant region S .
what leads to
ABk =C, (A.5)
with C = A0Bk0, where A(0) = A0 > 0,B(0) = B0 > 0. Thus, the orbits correspond to hyperbolas. Some
orbits together with the velocity field are shown in Fig. 8. We want to note that the center manifold is
given by the red line joining the points (1,0) and (0,1).
The feasible region of our model is the set
S = {(A,B) : A,B > 0, A+B 6 1}.
Since the set S is bounded by the center manifold and by the line orbits of the saddle point A = 0 and
B = 0, it is straightforward to see that the region S is an invariant region, that is, all the orbits inside S
belong to S for all times t ∈ R. Therefore, all the orbits inside S start and end in the center manifold
(except for the line orbits asymptotically approaching the saddle point (0,0) for t =±∞).
A.3 Exact solutions
It is interesting to note that in special cases it is possible to compute some explicit solutions for equations
(A.1). One of the most relevant cases corresponds to k = 1, that, as has been discussed through the paper,
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is the biologically most relevant situation. In that case, substituting the orbits equation, AB=C in (A.1b)
we get ∫ dB
(B− 12 )2 +C− 14
= ρ(t− t0) (A.6)
It is interesting to note that for solutions starting in the feasible region A+B6 1 a simple calculation
shows that 0 <C < 1/4. Let us define Q+ =
√
1
4 −C < 12 . In that case we can compute explicitly the
integrals in Eq. (A.6) to get
B(t) =
1
2
−Q+ tanh [Q+ρ(t− t0)] (A.7a)
A(t) =
C
1
2
−Q+ tanh [Q+ρ(t− t0)]
(A.7b)
In the phase space, these solutions correspond to hyperbolas inside the region S .
For the limit case C = 1/4, Eqs. (A.6) can be also solved explicitly to get
B(t) =
1
2
− 1ρ(t− t0) , (A.8a)
A(t) =
1
2− 4ρ(t− t0)
. (A.8b)
This is a special case, since that the solutions corresponds to hyperbolas through the point (1/2,1/2),
which is a point of the center manifold and for which λ2 = 0.
For completeness we also present the solutions for the case C > 1/4. In that case the solutions
correspond to hyperbolas outside the region S . Defining Q− =
√
C− 1/4 we get
B(t) =
1
2
+ Q− tan [Q−ρ(t− t0)] , (A.9a)
A(t) =
C
1
2
+Q− tan [Q−ρ(t− t0)]
. (A.9b)
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